Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, Rebar EJ, Reik A, Holmes MC, Gregory PD, Restifo NP, Rosenberg SA, Morgan RA, Feldman SA.

Mol Ther. 2015 Aug;23(8):1380-1390. doi: 10.1038/mt.2015.71. Epub 2015 May 5.

2.

Delayed administration of a bio-engineered zinc-finger VEGF-A gene therapy is neuroprotective and attenuates allodynia following traumatic spinal cord injury.

Figley SA, Liu Y, Karadimas SK, Satkunendrarajah K, Fettes P, Spratt SK, Lee G, Ando D, Surosky R, Giedlin M, Fehlings MG.

PLoS One. 2014 May 20;9(5):e96137. doi: 10.1371/journal.pone.0096137. eCollection 2014.

3.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH.

N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662.

4.

Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.

Siddiq I, Park E, Liu E, Spratt SK, Surosky R, Lee G, Ando D, Giedlin M, Hare GM, Fehlings MG, Baker AJ.

J Neurotrauma. 2012 Nov 20;29(17):2647-59. doi: 10.1089/neu.2012.2444. Epub 2012 Nov 9.

PMID:
23016562
5.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA.

Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.

6.

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M.

J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125.

PMID:
19752748
7.

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA.

J Immunol. 2007 Dec 1;179(11):7376-84.

8.

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD.

Cancer Res. 2006 Jan 15;66(2):1096-104.

9.

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.

Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr.

Nat Med. 2005 Aug;11(8):853-60. Epub 2005 Jul 24.

PMID:
16041382
10.

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL.

J Immunol. 2005 Jul 1;175(1):5-14. No abstract available.

11.

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.

12.

Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.

Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, Hinrichs DJ, Higgins DE, Miller JF, Giedlin M, Bouwer HG.

J Immunol. 2004 Jul 1;173(1):420-7.

13.
14.

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.

Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A.

Cancer Cell. 2002 May;1(4):325-37.

15.
16.

T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.

Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, Mule JJ.

Cancer Res. 2001 Mar 1;61(5):2062-70.

17.

Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction.

Roehl HH, Leibbrandt ME, Greengard JS, Kamantigue E, Glass WG, Giedlin M, Boekelheide K, Johnson DE, Jolly DJ, Sajjadi NC.

Hum Gene Ther. 2000 Dec 10;11(18):2529-40.

PMID:
11119423
18.

Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies.

Chang JW, Peng M, Vaquerano JE, Zhou YM, Clinton RA, Hyun WC, Giedlin MA, Leong SP.

Anticancer Res. 2000 May-Jun;20(3A):1329-36.

PMID:
10928040
19.

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.

Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO.

JAMA. 2000 Jul 12;284(2):183-9.

PMID:
10889591
20.

Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.

Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S67-75.

PMID:
10685663
21.

Characterization of novel antimicrobial peptoids.

Goodson B, Ehrhardt A, Ng S, Nuss J, Johnson K, Giedlin M, Yamamoto R, Moos WH, Krebber A, Ladner M, Giacona MB, Vitt C, Winter J.

Antimicrob Agents Chemother. 1999 Jun;43(6):1429-34.

22.

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.

Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC.

J Infect Dis. 1999 Apr;179(4):849-58.

PMID:
10068580
23.

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.

Shimizu K, Fields RC, Giedlin M, Mulé JJ.

Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2268-73.

24.

Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation.

Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT.

Mol Cell Biol. 1998 Oct;18(10):5699-711.

25.

The circulating common gamma chain (CD132) in inflammatory bowel disease.

Nielsen OH, Kirman I, Johnson K, Giedlin M, Ciardelli T.

Am J Gastroenterol. 1998 Mar;93(3):323-8.

PMID:
9517632
26.

Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency.

Dix RD, Giedlin M, Cousins SW.

Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1411-7.

PMID:
9191604
27.

Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.

Freedman RS, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA, Platsoucas CD.

J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):443-51.

PMID:
9041464
28.

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA.

Clin Cancer Res. 1996 Apr;2(4):669-77.

29.

IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors.

Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, Giedlin MA, Mullenbach G, Tekamp-Olson P.

J Immunol. 1995 Aug 1;155(3):1428-33.

PMID:
7636208
30.

The use of recombinant human interleukin-2 in treating infectious diseases.

Giedlin MA, Zimmerman RJ.

Curr Opin Biotechnol. 1993 Dec;4(6):722-6. Review.

PMID:
7764471
31.

T-cell antigen receptors with identical variable regions but different diversity and joining region gene segments have distinct specificities but cross-reactive idiotypes.

Rupp F, Brecher J, Giedlin MA, Mosmann T, Zinkernagel RM, Hengartner H, Joho RH.

Proc Natl Acad Sci U S A. 1987 Jan;84(1):219-22.

32.
33.

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL.

J Immunol. 1986 Apr 1;136(7):2348-57.

PMID:
2419430
34.

Murine T-cell clones specific for chicken erythrocyte alloantigens.

Giedlin MA, Longenecker BM, Mosmann TR.

Cell Immunol. 1986 Feb;97(2):357-70.

PMID:
2427220
35.

Variability and repertoire size of T-cell receptor V alpha gene segments.

Becker DM, Pattern P, Chien Y, Yokota T, Eshhar Z, Giedlin M, Gascoigne NR, Goodnow C, Wolf R, Arai K, et al.

Nature. 1985 Oct 3-9;317(6036):430-4.

PMID:
2995827
36.

Identification of Ia antigens on the murine adenocarcinoma LT-85.

Giedlin MA, Martin WJ, Callahan GN.

J Natl Cancer Inst. 1983 Oct;71(4):825-34.

PMID:
6578374
37.

Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma.

Callahan GN, Pardi D, Giedlin MA, Allison JP, Morizot DM, Martin WJ.

J Immunol. 1983 Jan;130(1):471-9.

PMID:
6847892
38.

Human acute myelogenous leukemia-associated antigens defined by a monkey antiserum to glycoproteins shed from leukemia myeloblasts.

Mohanakumar T, Giedlin MA, Baker MA, Roncari DA, Taub RN.

Leuk Res. 1981;5(1):11-7. No abstract available.

PMID:
6939949
39.

Relationship of B cell alloantibodies to renal allograft survival.

Mohanakumar T, Giedlin MA, Rhodes CL Jr, DuVall CH, Mendez-Picon G, Kaplan AM, Lee HM.

Transplantation. 1979 Apr;27(4):273-8.

PMID:
375503
40.

B-lymphocyte-specific antibodies in human renal allografts.

Mohanakumar T, Giedlin M, DuVall C, Rhodes C, Phibbs M, Mendez G, Kaplan AM, Lee HM.

Transplant Proc. 1979 Mar;11(1):397-400. No abstract available.

PMID:
377664

Supplemental Content

Loading ...
Support Center